Saturday 17 October 2026
Export CURX’s income statement to Excel — free account
Curanex Pharmaceuticals Inc
CURX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 4,671.4% and free cash flow fell 272.3%, each against the same quarter a year earlier.
4.62
0.21
−4.35%
Follow CURX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (411.10%) | (168.67%) | 0.00% | 0.00% |
+5 more TTM periods Free account |
|
| (357.22%) | (172.09%) | (72.97%) | (17.17%) | ||
ROIC |
(356.67%) | (112.15%) | (42.42%) | (9.16%) | |
Return on Tangible Assets |
(223.27%) | (90.87%) | (38.10%) | (8.74%) | |
Free Cash Flow per Share |
(8.52) | (7.97) | (8.22) | (7.60) | |
Free Cash Flow |
(12.08) | (11.29) | (10.48) | (9.72) | |
| Other line items | |||||
Cash ROIC |
(156.34%) | (93.32%) | (64.75%) | (48.32%) | |
Accounts Payable Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | (492.92) | — | |
Operating CF/Net income |
1.15 | 1.56 | 2.48 | 7.82 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(8.52) | (7.97) | (8.22) | (7.60) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates